Commentary: Does First-Line Treatment Impact Outcomes in Trisomy 21-Associated Infantile Epileptic Spasms Syndrome?
Journal of Experimental Neurology · 25.09.2026 · 7 (3) · 135
DOI: 10.33696/neurol.7.138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Neurology, online erschienen am 25.09.2026. Verfasst von Muzna AlFarsi und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Trisomy 21 (T21) is the most common chromosomal disorder and is associated with a substantially increased risk of epilepsy, affecting approximately 5–10% of children [1,2]. Among infants with T21, infantile epileptic spasms syndrome (IESS) is the most common epilepsy syndrome of the first year of life, with a reported prevalence of 0.6–13%, approximately 100-fold higher than in the general population [3,4].
Zitieren
APA
AlFarsi, M., & Datta, A. N. (2026). Commentary: Does First-Line Treatment Impact Outcomes in Trisomy 21-Associated Infantile Epileptic Spasms Syndrome?. Journal of Experimental Neurology, 7(3), 135. https://doi.org/10.33696/neurol.7.138
Vancouver
AlFarsi M, Datta AN. Commentary: Does First-Line Treatment Impact Outcomes in Trisomy 21-Associated Infantile Epileptic Spasms Syndrome?. Journal of Experimental Neurology. 2026;7(3):135. doi:10.33696/neurol.7.138
BibTeX
@article{AlFarsi2026,
author = {AlFarsi, Muzna and Datta, Anita N.},
title = {Commentary: Does First-Line Treatment Impact Outcomes in Trisomy 21-Associated Infantile Epileptic Spasms Syndrome?},
journal = {Journal of Experimental Neurology},
year = {2026},
volume = {7},
number = {3},
pages = {135},
doi = {10.33696/neurol.7.138}
}
EUVIMED